Inadequacies in the postnatal management of fetomaternal alloimmune thrombocytopenia (FMAIT)

Murphy, .; Verjee, Aly; Greaves,

doi:10.1046/j.1365-2141.1999.01276.x

Cited by 17 publications

(20 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have no explanation for this, allowing that most of the random PLTs must be matched with the maternal alloantibody. The use of washed and irradiated maternal PLTs was successful treatment when proposed, but there are logistic problems with this approach 13 . Antenatal therapy with maternal infusions of IVIG could be considered for women known to have a fetus at risk.…”

Section: Discussionmentioning

confidence: 99%

Anti‐HPA‐9bw (Max^a) fetomaternal alloimmunization, a clinically severe neonatal thrombocytopenia: difficulties in diagnosis and therapy and report on eight families

et al. 2005

View full text Add to dashboard Cite

This analysis confirms that anti-HPA-9bw (Max(a)) FMAIT is not uncommon and was found to be approximately 2 percent of our confirmed FMAIT cases. It is a clinically severe syndrome that requires prompt diagnosis, albeit difficult, and maternal PLT transfusion therapy. Laboratory investigation of a suspected FMAIT case should be carried out in a specialist laboratory well-experienced in optimal testing. Appropriate management and antenatal therapy should be considered for successive pregnancies to prevent fetal bleeding.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti‐HPA‐9bw (Max^a) fetomaternal alloimmunization, a clinically severe neonatal thrombocytopenia: difficulties in diagnosis and therapy and report on eight families

et al. 2005

View full text Add to dashboard Cite

show abstract

“…When asked about their preferred initial treatment of an infant with a provisional diagnosis of fetomaternal alloimmune thrombocytopenia and unknown specificity of the maternal antibodies, only 2 of 93 hematology departments in the United Kingdom selected random‐donor PLTs. HPA‐1a–negative PLT concentrates were the preferred choice by 19 hospitals, maternal PLTs by 18, and IVIG by 14 hospitals 27 . The results may not be representative, however, because of the low response rate (31%) to the questionnaire.…”

Section: Discussionmentioning

confidence: 87%

A systematic review and survey of the management of unexpected neonatal alloimmune thrombocytopenia

Bassler

Greinacher²,

Okascharoen³

et al. 2007

Transfusion

View full text Add to dashboard Cite

BACKGROUND: Unexpected neonatal alloimmune thrombocytopenia (NAIT) may have devastating consequences and its management is challenging. To design future trials, evidence from the literature and existing best practice need review. STUDY DESIGN AND METHODS: This study was a cross‐sectional survey of neonatal units in Germany and Canada to determine management strategies of NAIT and a systematic search for randomized controlled trials (RCTs). RESULTS: Management of NAIT differs substantially between countries with regard to platelet (PLT) thresholds for screening, initiation of therapy, and treatment. Seventy‐seven percent of Canadian physicians versus 68 percent of German physicians screen preterm and term infants, at a PLT threshold of 30 × 109 to 100 × 109 per L. In preterm infants, 60 percent of Canadian neonatologists commence treatment at a PLT count of between 30 × 109 and 50 × 109 per L. In Germany 32 percent of the physicians start treatment at this level and 25 percent use a threshold of between 10 × 109 and 20 × 109 per L. In term infants, 6 percent of the Canadian physicians and 16 percent of the German physicians use even lower treatment triggers of between 5 × 109 and 10 × 109 per L. In the presence of bleeding, 61 percent of German physicians await the arrival of antigen‐negative PLTs, while 64 percent of Canadian neonatologists prefer intravenous immunoglobulin or random‐donor PLTs (81%). Maternal PLTs are utilized by 31 percent of physicians in both countries. No RCTs were identified. CONCLUSION: In the absence of RCTs, management of unexpected NAIT differs between countries. Clinicians and transfusion services may use the results of our study to develop collaborative protocols, redefine preferred hospitalwide strategies, and design future controlled trials.

show abstract

“…Delays in treating the condition are mainly because of delays in diagnosis,9 which can lead to death or lasting disability in an affected baby.…”

Section: Discussionmentioning

confidence: 99%

Neonatal alloimmune thrombocytopenia

Rayment

Birchall²,

Yarranton³

et al. 2003

BMJ

View full text Add to dashboard Cite

show abstract

Inadequacies in the postnatal management of fetomaternal alloimmune thrombocytopenia (FMAIT)

Cited by 17 publications

References 3 publications

Anti‐HPA‐9bw (Max^a) fetomaternal alloimmunization, a clinically severe neonatal thrombocytopenia: difficulties in diagnosis and therapy and report on eight families

Anti‐HPA‐9bw (Max^a) fetomaternal alloimmunization, a clinically severe neonatal thrombocytopenia: difficulties in diagnosis and therapy and report on eight families

A systematic review and survey of the management of unexpected neonatal alloimmune thrombocytopenia

Neonatal alloimmune thrombocytopenia

Contact Info

Product

Resources

About

Inadequacies in the postnatal management of fetomaternal alloimmune thrombocytopenia (FMAIT)

Cited by 17 publications

References 3 publications

Anti‐HPA‐9bw (Maxa) fetomaternal alloimmunization, a clinically severe neonatal thrombocytopenia: difficulties in diagnosis and therapy and report on eight families

Anti‐HPA‐9bw (Maxa) fetomaternal alloimmunization, a clinically severe neonatal thrombocytopenia: difficulties in diagnosis and therapy and report on eight families

A systematic review and survey of the management of unexpected neonatal alloimmune thrombocytopenia

Neonatal alloimmune thrombocytopenia

Contact Info

Product

Resources

About

Anti‐HPA‐9bw (Max^a) fetomaternal alloimmunization, a clinically severe neonatal thrombocytopenia: difficulties in diagnosis and therapy and report on eight families

Anti‐HPA‐9bw (Max^a) fetomaternal alloimmunization, a clinically severe neonatal thrombocytopenia: difficulties in diagnosis and therapy and report on eight families